Title: Prognostic Factors for the Efficacy of Infliximab in Patients with Luminal Fistulizing
Crohn’s Disease
Version: 2 Date: 28 Dec 2022
Reviewer's report:
A decent retrospective study; although fraught with limitations.
The authors should clarify the lack of effective use of MRI and therapeutic drug monitoring in
the present era.
The following are suggested to enhance the manuscript:
1. How many patients had MRI as part of evaluation? Please clarify
2. The methods section needs to be elaborate
3. The numbers are too less to develop a nomogram; requires prospective validation
4. The following needs to be discussed as the discussion is lacking comparison with relevant
available data:
a. Braithwaite GC, Lee MJ, Hind D, Brown SR. Prognostic factors affecting outcomes
in fistulating perianal Crohn's disease: a systematic review. Tech Coloproctol. 2017
Jul;21(7):501-519. doi: 10.1007/s10151-017-1647-3. Epub 2017 Jun 20. PMID: 28639073;
PMCID: PMC5550543.
b. Sun XL, Chen SY, Tao SS, Qiao LC, Chen HJ, Yang BL. Optimized timing of using infliximab
in perianal fistulizing Crohn's disease. World J Gastroenterol. 2020 Apr 14;26(14):1554-1563.
doi: 10.3748/wjg.v26.i14.1554. PMID: 32327905; PMCID: PMC7167413.
c. Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with
perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. World J Gastroenterol.
2017 Sep 14;23(34):6197-6200. doi: 10.3748/wjg.v23.i34.6197. PMID: 28974885; PMCID:
PMC5603485.
d. Thomassin L, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, Savoye-
Collet C. Magnetic resonance imaging may predict deep remission in patients with perianal
fistulizing Crohn's disease. World J Gastroenterol. 2017 Jun 21;23(23):4285-4292. doi: 10.3748/
wjg.v23.i23.4285. PMID: 28694669; PMCID: PMC5483503.
e. Billiet T, Cleynen I, Ballet V, Ferrante M, Van Assche G, Gils A, Vermeire S. Prognostic
factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre
experience. Aliment Pharmacol Ther. 2016 Oct;44(7):673-83. doi: 10.1111/apt.13754. Epub
2016 Aug 9. PMID: 27502581.
f. Gu B, Venkatesh K, Williams AJ, Ng W, Corte C, Gholamrezaei A, Ghaly S, Xuan W,
Paramsothy S, Connor S. Higher infliximab and adalimumab trough levels are associated with
fistula healing in patients with fistulising perianal Crohn's disease. World J Gastroenterol.
2022 Jun 21;28(23):2597-2608. doi: 10.3748/wjg.v28.i23.2597. PMID: 35949350; PMCID:
PMC9254145.
g. De Gregorio M, Lee T, Krishnaprasad K, Amos G, An YK, Bastian-Jordan M, Begun J,
Borok N, Brown DJM, Cheung W, Connor SJ, Gerstenmaier J, Gilbert LE, Gilmore R, Gu B,
Kutaiba N, Lee A, Mahy G, Srinivasan A, Thin L, Thompson AJ, Welman CJ, Yong EXZ,
De Cruz P, van Langenberg D, Sparrow MP, Ding NS. Higher Anti-tumor Necrosis Factor-
# Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas. Clin
Gastroenterol Hepatol. 2022 Jun;20(6):1306-1314. doi: 10.1016/j.cgh.2021.07.053. Epub 2021
Aug 11. PMID: 34389484.
Title: Prognostic Factors for the Efficacy of Infliximab in Patients with Luminal Fistulizing
Crohn’s Disease
Version: 2 Date: 28 Dec 2022
Reviewer's report:
A decent retrospective study; although fraught with limitations.
The authors should clarify the lack of effective use of MRI and therapeutic drug monitoring in
the present era.
The following are suggested to enhance the manuscript:
1. How many patients had MRI as part of evaluation? Please clarify
2. The methods section needs to be elaborate
3. The numbers are too less to develop a nomogram; requires prospective validation
4. The following needs to be discussed as the discussion is lacking comparison with relevant
available data:
a. Braithwaite GC, Lee MJ, Hind D, Brown SR. Prognostic factors affecting outcomes
in fistulating perianal Crohn's disease: a systematic review. Tech Coloproctol. 2017
Jul;21(7):501-519. doi: 10.1007/s10151-017-1647-3. Epub 2017 Jun 20. PMID: 28639073;
PMCID: PMC5550543.
b. Sun XL, Chen SY, Tao SS, Qiao LC, Chen HJ, Yang BL. Optimized timing of using infliximab
in perianal fistulizing Crohn's disease. World J Gastroenterol. 2020 Apr 14;26(14):1554-1563.
doi: 10.3748/wjg.v26.i14.1554. PMID: 32327905; PMCID: PMC7167413.
c. Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with
perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. World J Gastroenterol.
2017 Sep 14;23(34):6197-6200. doi: 10.3748/wjg.v23.i34.6197. PMID: 28974885; PMCID:
PMC5603485.
d. Thomassin L, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, Savoye-
Collet C. Magnetic resonance imaging may predict deep remission in patients with perianal
fistulizing Crohn's disease. World J Gastroenterol. 2017 Jun 21;23(23):4285-4292. doi: 10.3748/
wjg.v23.i23.4285. PMID: 28694669; PMCID: PMC5483503.
e. Billiet T, Cleynen I, Ballet V, Ferrante M, Van Assche G, Gils A, Vermeire S. Prognostic
factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre
experience. Aliment Pharmacol Ther. 2016 Oct;44(7):673-83. doi: 10.1111/apt.13754. Epub
2016 Aug 9. PMID: 27502581.
f. Gu B, Venkatesh K, Williams AJ, Ng W, Corte C, Gholamrezaei A, Ghaly S, Xuan W,
Paramsothy S, Connor S. Higher infliximab and adalimumab trough levels are associated with
fistula healing in patients with fistulising perianal Crohn's disease. World J Gastroenterol.
2022 Jun 21;28(23):2597-2608. doi: 10.3748/wjg.v28.i23.2597. PMID: 35949350; PMCID:
PMC9254145.
g. De Gregorio M, Lee T, Krishnaprasad K, Amos G, An YK, Bastian-Jordan M, Begun J,
Borok N, Brown DJM, Cheung W, Connor SJ, Gerstenmaier J, Gilbert LE, Gilmore R, Gu B,
Kutaiba N, Lee A, Mahy G, Srinivasan A, Thin L, Thompson AJ, Welman CJ, Yong EXZ,
De Cruz P, van Langenberg D, Sparrow MP, Ding NS. Higher Anti-tumor Necrosis Factor-
# Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas. Clin
Gastroenterol Hepatol. 2022 Jun;20(6):1306-1314. doi: 10.1016/j.cgh.2021.07.053. Epub 2021
Aug 11. PMID: 34389484.
Please review this paper.
user
Title: Prognostic Factors for the Efficacy of Infliximab in Patients with Luminal Fistulizing
Crohn’s Disease
Version: 2 Date: 28 Dec 2022
Reviewer's report:
A decent retrospective study; although fraught with limitations.
The authors should clarify the lack of effective use of MRI and therapeutic drug monitoring in
the present era.
The following are suggested to enhance the manuscript:
1. How many patients had MRI as part of evaluation? Please clarify
2. The methods section needs to be elaborate
3. The numbers are too less to develop a nomogram; requires prospective validation
4. The following needs to be discussed as the discussion is lacking comparison with relevant
available data:
a. Braithwaite GC, Lee MJ, Hind D, Brown SR. Prognostic factors affecting outcomes
in fistulating perianal Crohn's disease: a systematic review. Tech Coloproctol. 2017
Jul;21(7):501-519. doi: 10.1007/s10151-017-1647-3. Epub 2017 Jun 20. PMID: 28639073;
PMCID: PMC5550543.
b. Sun XL, Chen SY, Tao SS, Qiao LC, Chen HJ, Yang BL. Optimized timing of using infliximab
in perianal fistulizing Crohn's disease. World J Gastroenterol. 2020 Apr 14;26(14):1554-1563.
doi: 10.3748/wjg.v26.i14.1554. PMID: 32327905; PMCID: PMC7167413.
c. Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with
perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. World J Gastroenterol.
2017 Sep 14;23(34):6197-6200. doi: 10.3748/wjg.v23.i34.6197. PMID: 28974885; PMCID:
PMC5603485.
d. Thomassin L, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, Savoye-
Collet C. Magnetic resonance imaging may predict deep remission in patients with perianal
fistulizing Crohn's disease. World J Gastroenterol. 2017 Jun 21;23(23):4285-4292. doi: 10.3748/
wjg.v23.i23.4285. PMID: 28694669; PMCID: PMC5483503.
e. Billiet T, Cleynen I, Ballet V, Ferrante M, Van Assche G, Gils A, Vermeire S. Prognostic
factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre
experience. Aliment Pharmacol Ther. 2016 Oct;44(7):673-83. doi: 10.1111/apt.13754. Epub
2016 Aug 9. PMID: 27502581.
f. Gu B, Venkatesh K, Williams AJ, Ng W, Corte C, Gholamrezaei A, Ghaly S, Xuan W,
Paramsothy S, Connor S. Higher infliximab and adalimumab trough levels are associated with
fistula healing in patients with fistulising perianal Crohn's disease. World J Gastroenterol.
2022 Jun 21;28(23):2597-2608. doi: 10.3748/wjg.v28.i23.2597. PMID: 35949350; PMCID:
PMC9254145.
g. De Gregorio M, Lee T, Krishnaprasad K, Amos G, An YK, Bastian-Jordan M, Begun J,
Borok N, Brown DJM, Cheung W, Connor SJ, Gerstenmaier J, Gilbert LE, Gilmore R, Gu B,
Kutaiba N, Lee A, Mahy G, Srinivasan A, Thin L, Thompson AJ, Welman CJ, Yong EXZ,
De Cruz P, van Langenberg D, Sparrow MP, Ding NS. Higher Anti-tumor Necrosis Factor-
# Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas. Clin
Gastroenterol Hepatol. 2022 Jun;20(6):1306-1314. doi: 10.1016/j.cgh.2021.07.053. Epub 2021
Aug 11. PMID: 34389484.
assistant